Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation.
Le Blanc
Katarina
K
Division of Clinical Immunology, F79 Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden. Katarina.Leblanc@medhs.ki.se.
Ringdén
Olle
O
D000917:Antibody Formation; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology*; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology*; D002450:Cell Communication; D002454:Cell Differentiation; D000939:Epitopes; D005434:Flow Cytometry; D005786:Gene Expression Regulation / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy; D007376:Interleukin-2 / Q000235:genetics; D007519:Isoantigens / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology; D010641:Phenotype; D016176:T-Lymphocyte Subsets / Q000166:cytology*; D014158:Transcription, Genetic
D000939:Epitopes; D007376:Interleukin-2; D007519:Isoantigens